Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasm, Residual × Doxorubicin × 30 days × Clear all

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 11 Burkitt Lymphoma 10 Neoplasms 8 Lymphoma, Follicular 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Ovarian Neoplasms 5 Lymphoma 5 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasm Metastasis 4 Lymphoma, Non-Hodgkin 4 Hodgkin Disease 4 Fallopian Tube Neoplasms 4 Sarcoma 3 Recurrence 3 Lymphoma, B-Cell, Marginal Zone 3 Liposarcoma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia, Biphenotypic, Acute 3 Endometrial Neoplasms 3 Sarcoma, Ewing 2 Osteosarcoma 2 Leiomyosarcoma 2 Histiocytoma, Malignant Fibrous 2 Wilms Tumor 1 Waldenstrom Macroglobulinemia 1 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Thymoma 1

Interventions

pembrolizumab 2 fludarabine 2 blinatumomab 2 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 relugolix 1 nilotinib 1 isatuximab 1 inavolisib 1 giredestrant 1 fludarabine phosphate 1 enzalutamide 1 abemaciclib 1 Transplantation 1 Monatide (IMS 3015) 1 Melphalan 1 Lenalidomide 1 Immunotherapy 1 Imatinib Mesylate 1 HMPL-013 1 Docetaxel 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Capecitabine 1 Calcium Dobesilate 1 Biological Assay 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡